Acoramidis Shows Significant Long-Term Benefits in Heart Failure Treatment
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 10 hours ago
0mins
Should l Buy BBIO?
Source: Newsfilter
- Significant Risk Reduction: In the ATTRibute-CM open-label extension trial, acoramidis achieved a 44.7% reduction in all-cause mortality (ACM) (p<0.0001) and a 49.3% reduction in cardiovascular mortality (CVM) (p<0.0001) at Month 54, marking the earliest timepoint for such significant risk reduction in this field, indicating its potential in heart disease treatment.
- Quality of Life Improvement: Early and continuous treatment with acoramidis effectively stabilized and maintained heart failure-related quality of life scores (KCCQ-OS), demonstrating a sustained improvement in the quality of life for ATTR-CM patients, thereby enhancing their overall health status.
- Good Safety Profile: Throughout the 54-month observation period, acoramidis exhibited a favorable long-term safety profile with no severe adverse reactions, providing confidence for its acceptability and tolerability in heart disease treatment for future clinical applications.
- Clinically Significant Findings: These study results underscore the importance of early diagnosis and timely treatment, as the sustained clinical benefits of acoramidis offer new hope for heart disease patients, potentially altering the treatment trajectory of this condition.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy BBIO?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on BBIO
Wall Street analysts forecast BBIO stock price to rise
13 Analyst Rating
13 Buy
0 Hold
0 Sell
Strong Buy
Current: 69.700
Low
85.00
Averages
98.50
High
157.00
Current: 69.700
Low
85.00
Averages
98.50
High
157.00
About BBIO
BridgeBio Pharma, Inc. is a biopharmaceutical company. It discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases. Its pipeline of development programs ranges from early science to advanced clinical trials, which includes Attruby, an oral small molecule near-complete transthyretin (TTR) stabilizer, for the treatment of cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis (ATTR-CM); Beyonttra for the treatment of TTR Amyloidosis; Low-dose Infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor (TKI) for the treatment of children with achondroplasia and hypochondroplasia; Encaleret, an oral small molecule antagonist of the calcium sensing receptor (CaSR) that it is developing for the treatment of Autosomal Dominant Hypocalcemia Type 1 (ADH1), and BBP-418, for the treatment of Limb Girdle Muscular Dystrophy Type 2I. It also conducting a Phase 1/2 study (CANaspire) for BBP-812 for Canavan disease.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Acoramidis Shows Significant Long-Term Benefits in Heart Failure Treatment
- Significant Risk Reduction: In the ATTRibute-CM open-label extension trial, acoramidis achieved a 44.7% reduction in all-cause mortality (ACM) (p<0.0001) and a 49.3% reduction in cardiovascular mortality (CVM) (p<0.0001) at Month 54, marking the earliest timepoint for such significant risk reduction in this field, indicating its potential in heart disease treatment.
- Quality of Life Improvement: Early and continuous treatment with acoramidis effectively stabilized and maintained heart failure-related quality of life scores (KCCQ-OS), demonstrating a sustained improvement in the quality of life for ATTR-CM patients, thereby enhancing their overall health status.
- Good Safety Profile: Throughout the 54-month observation period, acoramidis exhibited a favorable long-term safety profile with no severe adverse reactions, providing confidence for its acceptability and tolerability in heart disease treatment for future clinical applications.
- Clinically Significant Findings: These study results underscore the importance of early diagnosis and timely treatment, as the sustained clinical benefits of acoramidis offer new hope for heart disease patients, potentially altering the treatment trajectory of this condition.
See More
BridgeBio Submits NDA for BBP-418 to Treat LGMD2I/R9
- Clinical Trial Success: BridgeBio's BBP-418 met all pre-specified primary and secondary endpoints in the Phase 3 FORTIFY trial, demonstrating rapid and consistent treatment effects with a favorable safety profile, laying a solid foundation for future FDA approval.
- NDA Submission: The company has submitted a New Drug Application for BBP-418 to the FDA, with approval anticipated in late 2026 to early 2027, which, if successful, would be the first treatment for LGMD2I/R9, addressing a significant unmet need in this area.
- Significant Market Potential: Approval of BBP-418 would provide the first effective treatment option for thousands of LGMD2I/R9 patients, potentially improving their quality of life and representing the first approved therapy for any form of LGMD, highlighting its substantial market significance.
- Expedited Approval Pathway: BridgeBio is actively engaging with regulatory agencies to identify an expedited approval pathway for BBP-418 in Europe, while the drug has already received Orphan Drug, Fast Track, and Rare Pediatric Disease designations from the FDA, enhancing its market prospects.
See More
BridgeBio Pharma (BBIO.US) Director Plans to Sell $9.52 Million in Common Stock via Form 144
Share Sale Announcement: Bridge Bio Pharma intends to sell 140,000 shares of its common stock, valued at approximately $9.52 million, on March 13.
Reduction in Holdings: The Kumar Haldea Family Irrevocable Trust has reduced its shareholding in Bridge Bio Pharma by 25,806 shares since December 15, 2025, with a total value of around $18.78 million.
See More
BridgeBio Presents Positive Interim Data for BBP-418 in LGMD2I/R9
- Clinical Trial Results: BridgeBio presented positive interim analysis results for BBP-418 at the MDA conference, highlighting early separation from placebo in the 100-meter timed test, with improvements evident as early as three months, indicating the drug's rapid onset of action.
- FDA Submission Plans: Following the positive interim results, BridgeBio intends to submit a New Drug Application (NDA) to the FDA in the first half of 2026, with a U.S. launch anticipated in late 2026 to early 2027, potentially making it the first approved therapy for LGMD2I/R9, which holds significant market potential.
- Safety Analysis: BBP-418 demonstrated a safety profile comparable to placebo, with 93.2% of patients reporting treatment-emergent adverse events, and similar rates of serious adverse events, indicating good tolerability and laying a foundation for future clinical use.
- Efficacy Sustainability: Among patients treated with BBP-418 for 12 months, 59.6% achieved significant reductions in serum creatine kinase (CK) levels, and 38.3% normalized CK levels, demonstrating the drug's sustained efficacy in improving muscle function, which could transform the treatment landscape for LGMD2I/R9.
See More
BridgeBio Pharma Stock Soars on Price Target Upgrade
- Stock Surge: BridgeBio Pharma's shares jumped 13.22% on Tuesday, closing at $74.32, driven by a double-digit price target upgrade from an investment firm, indicating strong market confidence in its future performance.
- Price Target Increase: JPMorgan raised BridgeBio's price target from $89 to $94, representing a 26% upside potential from its latest closing price, further solidifying its 'overweight' rating and reflecting analysts' optimism about the company's prospects.
- Clinical Trial Data: At the MDA Clinical and Scientific Conference in Orlando, Florida, BridgeBio presented data from its third-phase clinical trial for BBP-418 in patients with limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9), showing a statistically significant 2.6-point improvement in NSAD compared to placebo, indicating the therapy's efficacy.
- FDA Recommendation: The company stated that the FDA recommended pursuing traditional approval for BBP-418, with plans to submit a new drug application in the first half of the year and an expected official launch later this year or early 2027, marking a significant advancement in its treatment pipeline.
See More
U.S. Markets Closed with Mixed Results on Tuesday, Driven by BridgeBio Pharma's Gains and Centene's Declines
- U.S. Stock Market Performance: U.S. stock indexes closed mixed on Tuesday, with overall performance remaining flat.
- Index Movements: The Dow Jones Industrial Average dropped by 0.07%, while the S&P 500 fell by 0.21%.
See More
Acoramidis Shows Significant Long-Term Benefits in Heart Failure Treatment
- Significant Risk Reduction: In the ATTRibute-CM open-label extension trial, acoramidis achieved a 44.7% reduction in all-cause mortality (ACM) (p<0.0001) and a 49.3% reduction in cardiovascular mortality (CVM) (p<0.0001) at Month 54, marking the earliest timepoint for such significant risk reduction in this field, indicating its potential in heart disease treatment.
- Quality of Life Improvement: Early and continuous treatment with acoramidis effectively stabilized and maintained heart failure-related quality of life scores (KCCQ-OS), demonstrating a sustained improvement in the quality of life for ATTR-CM patients, thereby enhancing their overall health status.
- Good Safety Profile: Throughout the 54-month observation period, acoramidis exhibited a favorable long-term safety profile with no severe adverse reactions, providing confidence for its acceptability and tolerability in heart disease treatment for future clinical applications.
- Clinically Significant Findings: These study results underscore the importance of early diagnosis and timely treatment, as the sustained clinical benefits of acoramidis offer new hope for heart disease patients, potentially altering the treatment trajectory of this condition.
See More
BridgeBio Submits NDA for BBP-418 to Treat LGMD2I/R9
- Clinical Trial Success: BridgeBio's BBP-418 met all pre-specified primary and secondary endpoints in the Phase 3 FORTIFY trial, demonstrating rapid and consistent treatment effects with a favorable safety profile, laying a solid foundation for future FDA approval.
- NDA Submission: The company has submitted a New Drug Application for BBP-418 to the FDA, with approval anticipated in late 2026 to early 2027, which, if successful, would be the first treatment for LGMD2I/R9, addressing a significant unmet need in this area.
- Significant Market Potential: Approval of BBP-418 would provide the first effective treatment option for thousands of LGMD2I/R9 patients, potentially improving their quality of life and representing the first approved therapy for any form of LGMD, highlighting its substantial market significance.
- Expedited Approval Pathway: BridgeBio is actively engaging with regulatory agencies to identify an expedited approval pathway for BBP-418 in Europe, while the drug has already received Orphan Drug, Fast Track, and Rare Pediatric Disease designations from the FDA, enhancing its market prospects.
See More
BridgeBio Pharma (BBIO.US) Director Plans to Sell $9.52 Million in Common Stock via Form 144
Share Sale Announcement: Bridge Bio Pharma intends to sell 140,000 shares of its common stock, valued at approximately $9.52 million, on March 13.
Reduction in Holdings: The Kumar Haldea Family Irrevocable Trust has reduced its shareholding in Bridge Bio Pharma by 25,806 shares since December 15, 2025, with a total value of around $18.78 million.
See More
BridgeBio Presents Positive Interim Data for BBP-418 in LGMD2I/R9
- Clinical Trial Results: BridgeBio presented positive interim analysis results for BBP-418 at the MDA conference, highlighting early separation from placebo in the 100-meter timed test, with improvements evident as early as three months, indicating the drug's rapid onset of action.
- FDA Submission Plans: Following the positive interim results, BridgeBio intends to submit a New Drug Application (NDA) to the FDA in the first half of 2026, with a U.S. launch anticipated in late 2026 to early 2027, potentially making it the first approved therapy for LGMD2I/R9, which holds significant market potential.
- Safety Analysis: BBP-418 demonstrated a safety profile comparable to placebo, with 93.2% of patients reporting treatment-emergent adverse events, and similar rates of serious adverse events, indicating good tolerability and laying a foundation for future clinical use.
- Efficacy Sustainability: Among patients treated with BBP-418 for 12 months, 59.6% achieved significant reductions in serum creatine kinase (CK) levels, and 38.3% normalized CK levels, demonstrating the drug's sustained efficacy in improving muscle function, which could transform the treatment landscape for LGMD2I/R9.
See More
BridgeBio Pharma Stock Soars on Price Target Upgrade
- Stock Surge: BridgeBio Pharma's shares jumped 13.22% on Tuesday, closing at $74.32, driven by a double-digit price target upgrade from an investment firm, indicating strong market confidence in its future performance.
- Price Target Increase: JPMorgan raised BridgeBio's price target from $89 to $94, representing a 26% upside potential from its latest closing price, further solidifying its 'overweight' rating and reflecting analysts' optimism about the company's prospects.
- Clinical Trial Data: At the MDA Clinical and Scientific Conference in Orlando, Florida, BridgeBio presented data from its third-phase clinical trial for BBP-418 in patients with limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9), showing a statistically significant 2.6-point improvement in NSAD compared to placebo, indicating the therapy's efficacy.
- FDA Recommendation: The company stated that the FDA recommended pursuing traditional approval for BBP-418, with plans to submit a new drug application in the first half of the year and an expected official launch later this year or early 2027, marking a significant advancement in its treatment pipeline.
See More
U.S. Markets Closed with Mixed Results on Tuesday, Driven by BridgeBio Pharma's Gains and Centene's Declines
- U.S. Stock Market Performance: U.S. stock indexes closed mixed on Tuesday, with overall performance remaining flat.
- Index Movements: The Dow Jones Industrial Average dropped by 0.07%, while the S&P 500 fell by 0.21%.
See More
